The research-grade biosimilar is a humanised IgG1 kappa monoclonal antibody that acts as an antagonist for IL-5. IL-5 is a major cytokine that plays an important role in the recruitment, activation, growth, differentiation, and survival of eosinophil cells. The antibody binds to IL-5 and inhibits its interaction with the IL-5 receptor, localised on the surface of eosinophil cells. This prevents IL-5 mediated signaling and results in reduced survival of eosinophil cells and reduced inflammation. The original drug received approval from the FDA in 2015 for the treatment of severe eosinophilic asthma.
In PBS, pH 7.5